Introduction
============

Vitamin A is obtained through the diet in the form of retinol, retinyl ester or β-carotene ([@b1-ijo-44-06-1831]). Retinoic acid (RA) is one of the principal active metabolites of vitamin A which plays a critical role in cell proliferation, differentiation and apoptosis in normal tissues during embryonic development ([@b2-ijo-44-06-1831]). RA induces differentiation in many cell types and is the most widely used differentiating therapeutic agent ([@b3-ijo-44-06-1831],[@b4-ijo-44-06-1831]). Retinol has 6 biologically active isoforms that among others includes all-trans (ATRA, tretinoin) and 9-cis RA (alitretinoin); ATRA is the predominant physiological form ([@b5-ijo-44-06-1831]). RA mediates the transcriptional regulation of several genes by binding to the nuclear retinoic acid receptors (RARs), namely RARα, RARβ and RARγ ([@b6-ijo-44-06-1831],[@b7-ijo-44-06-1831]). Like other nuclear receptors, RARs contain a domain that mediates interaction with ATRA, a zinc finger-containing DNA binding domain that binds to RA response elements (RAREs) in target genes, and a dimerization domain that engages members of the retinoid X receptor (RXR) subfamily in RXR/RAR heterodimers ([@b8-ijo-44-06-1831]). Different isomers activate different receptors and thus lead to different biological effects. RARs can be activated by both all-trans (ATRA) and 9-cis-RA, while RXR are exclusively activated by 9-cis RA; however, due to the conversion of ATRA to 9-cis RA, high concentrations (10^−5^ M) of ATRA can also activate gene transcription in cells transfected with RXRs ([@b9-ijo-44-06-1831]). It has also been shown that retinoids exert their effects via the nuclear receptor independent pathway ([@b5-ijo-44-06-1831]).

RA and its derivatives are promising anti-neoplastic agents endowed with both therapeutic and chemopreventive potential because they are able to regulate cell growth, differentiation and apoptosis ([@b10-ijo-44-06-1831],[@b11-ijo-44-06-1831]). It is believed that the anti-neoplastic pathways induced by RA are regulated predominantly by RAR-β, which is known to induce apoptosis; thus it has been suggested that RAR-β plays a critical role in mediating the growth arrest and differentiation in several breast cancer cell types ([@b12-ijo-44-06-1831]--[@b14-ijo-44-06-1831]).

We have developed an *in vitro*-*in vivo* model of breast cancer progression by treating the human normal-like breast epithelial cells MCF-10F with a high dose of estradiol (70 nM) ([Fig. 1](#f1-ijo-44-06-1831){ref-type="fig"}) ([@b15-ijo-44-06-1831],[@b16-ijo-44-06-1831]). This model consists of four cell lines: i) the spontaneously immortalized cell line MCF-10F, which is considered to be a normal-like breast epithelial cell line; ii) the transformed trMCF cells; iii) the invasive bsMCF cells; and iv) cells isolated from xenografts, caMCFs, which show all characteristics of fully malignant breast cancer cells ([Fig. 1](#f1-ijo-44-06-1831){ref-type="fig"}). Gene expression studies showed the highest number of deregulated genes in caMCF, being slightly lower in bsMCF, and lowest in trMCF and, this order was consistent with the extent of chromosome aberrations (caMCF\>bsMCF\>\>trMCF) ([@b16-ijo-44-06-1831]). This model of breast cancer progression resembles the different steps of neoplastic transformation of the mammary gland; it is widely held that breast cancer initiates as the premalignant stage of atypical ductal hyperplasia (ADH), progresses into the pre-invasive stage of ductal carcinoma *in situ* (DCIS), and culminates in the potentially lethal stage of invasive ductal carcinoma (IDC) ([@b17-ijo-44-06-1831]). In collagen, the normal-like MCF-10F cells form tubules resembling the structures observed in the normal mammary gland although after treatment with estradiol, the transformed trMCF cells form tubules and spherical masses, which are indicative of cell transformation ([@b8-ijo-44-06-1831],[@b19-ijo-44-06-1831]). The spherical masses showed a partial filling of the lumen that would result from decreased central apoptosis, enhanced cellular proliferation or both ([@b18-ijo-44-06-1831]). The filling of the lumen of the tubular structures of the breast is the earliest morphologic alteration and is common in atypical ductal hyperplasia and ductal carcinoma *in situ* (DCIS) ([@b18-ijo-44-06-1831]). In the presented study, we studied the effect of all trans-RA (ATRA) using this model of breast cancer progression. Our results showed that ATRA was able to re-program early transformed cells to a normal stage.

Materials and methods
=====================

Cells and media
---------------

The human normal-like breast epithelial cells MCF-10F are estrogen receptor (ER) negative, progesterone receptor (PR) negative and HER2 negative. Cells were cultured in Dulbecco's modified Eagle's medium \[DMEM/F-12, Gibco, Carlsbad, CA; formula 90--5212 EF: containing DMEM/F12 (1:1) with L-glutamine and phenol red, D-glucose 315 mg/l, sodium pyruvate 55 mg/l\] with 5% horse serum, 2.43 g/l sodium bicarbonate, 20 mg/l epidermal growth factor (EGF), 100 mg/l *Vibrio cholerae* toxin, 10 mg/l insulin, 0.5 mg/l hydrocortisone, 1.05 mM calcium, antibiotics and antimicotic (100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin). A 10-mM solution of all trans-retinoic acid (ATRA, Cat\# R2625, Sigma, St. Louis, MO) was prepared as a stock solution by dissolving ATRA in dimethylsulphoxide (DMSO).

The trMCF clone 11 was isolated by seeding 100--1,000 trMCF cells in a 100-mm cell culture plate and after 1 day in culture, several colonies were isolated by ring cloning. The trMCF clone 11 cells were generated by expanding the cells from one of these colonies; trMCF clone 11 cells only formed spherical masses on collagen. To study the effect of ATRA, trMCF clone 11 cells were treated continuously for 26 days with 10^−5^ M (10 *μ*M) to 10^−8^ M (0.01 *μ*M) ATRA (media was replaced daily). As control, the cells were treated with 0.1% DMSO (vehicle). The bsMCF and caMCF cells were treated with 10^−5^ to 10^−8^ M ATRA alone or in combination with 2.5 *μ*M 5-aza-dC.

Collagen assays
---------------

The cells were resuspended at a final density of 1.5×10^4^ cells/ml in collagen matrix consisting of 2.68 mg/ml (89.3%) type I collagen (PureCol, Inamed Biomaterials Co., Fremont, CA), 8% 12.5X DMEM-F12 with antibiotics, 0.1 mg/ml insulin, 14 mM NaHCO~3~ and 0.01 N NaOH. A total of 400 *μ*l (3,000 cells) were plated on the top four 24-well chambers pre-coated with 400 *μ*l of 89.3% collagen mix. Per each treatment, cells were plated in 4 wells and fed daily with the medium described before. The structures in collagen matrix were observed daily under an inverted microscope and at the end of the observation period (8 days), the structures (spherical masses, tubules and intermediate structures) were counted, photographed and fixed in 10% neutral buffered formalin and processed for histological examination. Results were expressed as the total number of structures per well (spherical masses, tubules and intermediate structures) and percentage of the different structures per treatment. The t-test was used to determine if the differences were significant.

Invasion assays
---------------

Cell invasion in real-time were performed using xCELLigence RTCA DP device from Roche Diagnostics (Mannheim, Germany). For this purpose, each well of the upper chamber of the CIM-Plate 16 was covered with Matrigel (BD Biosciences, Franklin Lakes, NJ) basement membrane matrix (1:20 in cell culture media) and 10% fetal bovine serum (chemo-attractant) was added in the lower chamber. A total of 40,000 cells suspended in 100 *μ*l serum free media were seeded per well in CIM-Plates 16 (Roche Diagnostics). Data acquisition and analysis was performed with the RTCA software (version 1.2, Roche Diagnostics). Changes in impedance from cells that invade and migrate to the underside of wells were recorded and monitored for a total of 24 h.

Gene expression profiling
-------------------------

RNA was isolated from the cells using RiboPure™ kit (Life Technologies, Frederick, MD) and RNA quality was controlled using the Agilent 2100 Bioanalyzer. Gene expression studies were performed using Affymetrix U133 Plus 2.0 (Affymetrix, Santa Clara, CA) human oligonucleotide microarrays containing over 47,000 transcripts and variants, including 38,500 well characterized human genes. After hybridization, the chips were scanned using GeneChip Scanner 3000. The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100. Background correction and normalization was done using Iterative Plier 16 with GeneSpring V11.5 software (Agilent, Palo Alto, CA). The criteria for differentially expressed genes was set at ≥2-fold changes (p-value \<0.05). The differentially expressed gene list was loaded into Ingenuity Pathway Analysis (IPA) 8.0 software (Ingenuity Systems, Redwood City, CA) to perform biological network and functional analyses.

Results
=======

Treatment with ATRA induced branching morphogenesis in early transformed breast epithelial cells
------------------------------------------------------------------------------------------------

MCF-10F cells are normal-like breast epithelial cells that form tubules in collagen matrix (3D culture); when these cells were treated with high dose of estradiol (70 nM), the cells (trMCF) formed tubules and spherical masses. To isolate transformed cells that only form spherical masses, trMCF cells were seeded at low density in cell culture dishes and several clones were isolated by ring cloning. One of these clones, trMCF clone 11, did not form tubules in collagen; instead these cells formed spherical masses and intermediate structures ([Fig. 2A and B](#f2-ijo-44-06-1831){ref-type="fig"}). The trMCF clone 11 cells were treated continuously for 26 days with 10^−5^ to 10^−8^ M all trans-retinoic acid (ATRA) and, we found that cells treated with 10^−5^ and 10^−6^ M ATRA were able to form tubules in collagen ([Fig. 2C and D](#f2-ijo-44-06-1831){ref-type="fig"}). Furthermore, the spherical masses formed by trMCF clone 11 treated with 10^−5^ and 10^−6^ M ATRA ([Fig. 2C and D](#f2-ijo-44-06-1831){ref-type="fig"}) were smaller compared to the ones formed by the controls ([Fig. 2A and B](#f2-ijo-44-06-1831){ref-type="fig"}) or cells treated with 10^−7^ and 10^−8^ M ATRA ([Fig. 2E and F](#f2-ijo-44-06-1831){ref-type="fig"}). The trMCF clone 11 cells treated with 10^−7^ and 10^−8^ M ATRA ([Fig. 2E and F](#f2-ijo-44-06-1831){ref-type="fig"}) did not show any difference in morphology when compared to the controls ([Fig. 2A and B](#f2-ijo-44-06-1831){ref-type="fig"}). The number of spherical masses, intermediate structures and tubules for trMCF clone 11 cells treated with different concentrations of ATRA was counted ([Fig. 3](#f3-ijo-44-06-1831){ref-type="fig"}). The total number of structures in collagen was significantly lower in cells treated with ATRA compared with the controls suggesting that ATRA treatment decrease the proliferation rate of the cells (p\<0.01) ([Fig. 3A](#f3-ijo-44-06-1831){ref-type="fig"}). The control trMCF clone 11 showed spherical masses and intermediate structures but no tubules in collagen while cells treated with 10^−6^ and 10^−5^ M ATRA formed tubules and less spherical masses ([Fig. 3A](#f3-ijo-44-06-1831){ref-type="fig"}). The cells treated with 10^−5^ or 10^−6^ M ATRA formed significantly less spherical masses than the cells treated with 10^−7^ or 10^−8^ M ATRA (p\<0.01) ([Fig. 3A](#f3-ijo-44-06-1831){ref-type="fig"}). A total of 43% of the structures were tubules in the wells containing cells treated with 10^−6^ M ATRA and 10% tubules in wells with 10^−5^ M ATRA-treated cells ([Fig. 3B](#f3-ijo-44-06-1831){ref-type="fig"}).

The invasion capacity of trMCF clone 11 was studied before and after ATRA treatment but, no differences were observed ([Fig. 4](#f4-ijo-44-06-1831){ref-type="fig"}). The bsMCF and caMCF cells did not show any changes in their morphology or invasion capacity after treatment with ATRA alone or in combination with the demethylating agent 5-aza-cytidine (data not shown).

Treatment with ATRA re-programmed gene expression of early transformed cells
----------------------------------------------------------------------------

As trMCF clone 11 cells that only formed spherical masses on collagen were able to form tubules after treatment with 10^−5^ or 10^−6^ M ATRA, gene expression studies were performed on these cells. The microarray data have been deposited into the NCBI gene expression omnibus (GEO) datasets (GSE51549). The unsupervised sample classification by PCoA (principle coordinate analysis) revealed that trMCF clone 11 cells treated with 10^−5^ or 10^−6^ M ATRA demonstrated a major difference with trMCF clone 11 cells, and a minor difference with MCF-10F; also sample differences between 10^−5^ M ATRA and 10^−6^ M ATRA were weak ([Fig. 5](#f5-ijo-44-06-1831){ref-type="fig"}). Although, trMCF clone 11 cells treated with 10^−5^ M ATRA and 10^−6^ M ATRA showed minor differences at the expression level, we considered trMCF clone 11 treated with 10^−6^ M ATRA for the expression analysis since the number of tubules in collagen matrix was higher for this concentration (43% tubules with 10^−6^ M ATRA vs. 10% tubules with 10^−5^ M ATRA). For gene expression studies, three experimental groups were compared using empirical Bayesian-moderated t-test implemented in R package 'limma': the normal breast epithelial cells MCF-10F, the cells transformed by treatment with estradiol trMCF clone 11 (that only formed spherical masses on collagen) and the trMCF clone 11 after treatment with 10^−6^ M ATRA. We generated three gene lists at criteria of fold change ≥2 and p≤0.05: gene list-1 (trMCF clone11 vs. MCF-10F) with 1,409 probes (613 probes upregulated; 796 probes downregulated), gene list-2 (ATRA trMCF clone 11 vs. trMCF clone 11) with 1,859 probe sets (1,053 probes upregulated; 806 probes downregulated) and gene list-3 (ATRA trMCF clone 11 vs. MCF-10F) with 870 probe sets (308 probes upregulated; 562 probes downregulated) ([Fig. 6](#f6-ijo-44-06-1831){ref-type="fig"}). Most importantly, 207 genes (271 probes) upregulated in the transformed trMCF clone 11 (compared to the normal MCF-10F) were downregulated after treatment with 10^−6^ M ATRA ([Fig. 6](#f6-ijo-44-06-1831){ref-type="fig"} and [Table IA](#t1A-ijo-44-06-1831){ref-type="table"}) and 236 genes (316 probes) that were downregulated in trMCF clone 11 (compared to MCF-10F) were upregulated by 10^−6^ M ATRA treatment ([Fig. 6](#f6-ijo-44-06-1831){ref-type="fig"} and [Table IB](#t1B-ijo-44-06-1831){ref-type="table"}). These 443 genes defined a gene signature programming the reverse-transformation effect by ATRA ([Table I](#t1-ijo-44-06-1831){ref-type="table"}). The relatively smaller number of significant probe sets in gene list-3 compared with other gene lists ([Fig. 6](#f6-ijo-44-06-1831){ref-type="fig"}) further supported the findings that ATRA-treatment reprograms the gene expression status of trMCF clone 11 cells to MCF-10F.

Ingenuity pathway analysis (IPA) revealed 4 canonical pathways significantly dysregulated in the transformed cells trMCF clone 11: aryl hydrocarbon receptor signaling, retinoic acid activation, xenobiotic metabolism signaling and molecular mechanism of cancer ([Table II](#t2-ijo-44-06-1831){ref-type="table"}). Several genes of these pathways that were up- or downregulated in trMCF clone 11 show similar levels of expression to MCF-10F after trMCF clone 11 was treated with 10^−6^ M ATRA ([Table II](#t2-ijo-44-06-1831){ref-type="table"} and [Fig. 7](#f7-ijo-44-06-1831){ref-type="fig"}). Genes from the aryl hydrocarbon receptor signaling ALDH1A3, CCND1, TGFBR2, TGM2 and TFDP1 were downregulated in the transformed cells trMCF clone 11 when compared to their expression in the normal breast epithelial cells MCF-10F and, the expression of these genes was upregulated after these cells were treated with 10^−6^ M ATRA reaching similar levels to the expression in MCF-10F ([Table II](#t2-ijo-44-06-1831){ref-type="table"} and [Fig. 7](#f7-ijo-44-06-1831){ref-type="fig"}). One of the functions that show enrichment of dysregulated genes in the transformed trMCF clone 11 cells is cell morphology and the expression of most of these genes reached similar levels to MCF-10F after trMCF cells were treated with 10^−6^ M ATRA. The expression of some genes related to cell morphology such as PLD1, CD44, STX6, STMN3, ATF2, ETS2, NEK2, HAS3, MGP, GNA13 were upregulated in the transformed trMCF clone 11 and their expression reached normal levels after 10^−6^ M ATRA treatment ([Fig. 7](#f7-ijo-44-06-1831){ref-type="fig"}); other genes related to cell morphology such as PHLDA1, GBP1, HS6ST2 and TLR3 were downregulated in trMCF clone 11 and their expressions increased after 10^−6^ M ATRA treatment reaching similar levels to those found in the normal MCF-10F breast epithelial cells ([Fig. 7](#f7-ijo-44-06-1831){ref-type="fig"}). Also, the expression of several genes that encode enzymes involved in chromatin modifications such as MGEA5, ATF-2, KDM5B, PRMT2 (PRM2), PHF21A and NSD1, were dysregulated in trMCF clone 11, reaching normal levels after 10^−6^ M ATRA treatment ([Fig. 7](#f7-ijo-44-06-1831){ref-type="fig"}).

Discussion
==========

In this study we showed that all trans-retinoic acid (ATRA) induced branching of early transformed human breast epithelial cells. The transformed trMCF clone 11 cells form spherical masses in collagen (3D culture) and treatment with 10^−6^ M ATRA produced a significant decrease in spherical masses and an increased number of tubules. Cells at an advanced stage of transformation (bsMCF and caMCF) did not show any change in morphology after being treated with ATRA. Our previous results showed that RARβ (retinoic acid receptor β) was unmethylated in MCF-10F and trMCF cells and became hypermethylated at the invasive (bsMCF) and tumorigenic (caMCF) stages ([@b19-ijo-44-06-1831]); although bsMCF and caMCF were treated with 5-aza-dC to reactivate the expression of RARβ in combination with ATRA, no changes in the phenotype of these cells in collagen were observed. Our results indicate that ATRA is able to re-differentiate early transformed cells to a normal stage but, not tumor cells at later stages of the neoplastic process. We previously showed that bsMCF and caMCF had important chromosomal gains and losses and the earlier transformed cells trMCF showed small genomic changes ([@b16-ijo-44-06-1831]); this could explain why ATRA was only effective as a re-differentiation agent in the early transformed breast epithelial cells. Different studies indicate that epigenetic modifications play important roles in RA transcriptional regulation ([@b20-ijo-44-06-1831]--[@b24-ijo-44-06-1831]). Histones have a long N-terminal tail extending outside the nucleosome that is subject to acetylation, phosphorylation, and methylation ([@b25-ijo-44-06-1831]). In the absence of RA, co-repressive elements (SMRT, NCoR and SIN3A) inhibit transcription; the presence of RA releases co-repressors and histone deacetylases allowing chromatin remodeling and access to specific RAREs ([@b20-ijo-44-06-1831],[@b24-ijo-44-06-1831]). RA treatment leads to acetylation of histones H3 and H4 that lead to a more open stage of the chromatin allowing the transcription of ATRA regulated genes. However, only a limited number of information is currently available on the epigenetic dynamics of RA response.

Recently, analysis of gene expression array datasets of different FDA approved drugs revealed that ATRA (tretinoin) is a drug that is negatively associated with cancer stem cell (CSC) enriched gene expression signature ([@b26-ijo-44-06-1831]). We found that ATRA treatment reduced the expression of the stem cell marker CD44 in early transformed cells. ATRA exerts effects on stem cell differentiation in part via the modulation of the epigenome. Numerous enzymes that alter the modifications on histones are involved in transcriptional activation of specific genes in stem cells, and many of these enzymes are modulated by RA treatment of stem cells ([@b27-ijo-44-06-1831]). The expression of several genes encoding enzymes involved in chromatin modifications such as MGEA5, ATF-2, KDM5B, PRMT2, PHF21A and NSD1 were dysregulated in trMCF clone 11, reaching normal levels after ATRA treatment. Others have shown that in breast cancer, retinoids are effective inhibitors of breast cancer cells at early stages of tumor progression, but their effectiveness diminishes as the tumors become more aggressive ([@b28-ijo-44-06-1831]). Our results support these findings.

Our results show that the RA concentration is important to induced re-differentiation of early transformed breast epithelial cells. The treatment of transformed cells with either 10^−7^ or 10^−8^ M ATRA did not induced any change in morphology although, cells were able to form tubules after treatment with 10^−5^ and 10^−6^ M ATRA, more tubules being developed after treatment with 10^−6^ M (1 *μ*M) ATRA.

Little is known about the genomic targets and effects of the different isoforms of the RARs and mechanism or extent of crosstalk between RA signaling and other signaling pathways. It has been recently shown that RAR binding through the genome is highly coincident with estrogen receptor α binding, resulting in widespread crosstalk of RA and estrogen signaling to antagonistically regulate breast-cancer associated genes ([@b29-ijo-44-06-1831]). Our gene expression studies determined 443 genes which defined a signature of ATRA re-programming effect in early transformed breast epithelial cells; these genes were dysregulated in the early transformed cells and they reached normal levels after the cells were treated with 10^−6^ M ATRA. Genes from the aryl hydrocarbon receptor (AhR), retinoic acid receptor (RAR) and the xenobiotic pathways were dysregulated in the early transformed breast epithelial cells and their expression reached normal levels after ATRA treatment. It has been shown that there is an interaction between AhR and RAR activation and that AhR not only binds to polycyclic aromatic hydrocarbon family of environmental contaminants but also to some synthetic retinoids ([@b30-ijo-44-06-1831],[@b31-ijo-44-06-1831]).

N-(4-hydoxyphenyl) retinamide (fenretinide or 4HPR) is a synthetic retinoid that is currently one of the most promising clinically tested retinoids. The modification of the carboxyl end of all-trans RA with N-4-hydroxyphenyl group resulted in increased efficacy as a chemoprevention agent as well as reduced toxicity when compared with other retinoids ([@b32-ijo-44-06-1831]). Animal models have demonstrated that treatment with fenretinide prevents chemically induced cancers of the breast, prostate, bladder and skin ([@b33-ijo-44-06-1831]--[@b36-ijo-44-06-1831]).

In conclusion, our results showed that 1 *μ*M ATRA was able to re-differentiate transformed cells at early stages of the neoplastic process and antagonistically regulated breast cancer associated genes. Our results support previous findings that 1 *μ*M ATRA could be used as a chemo-preventive agent to inhibit the progression of premalignant lesions of the breast.

We thank Karen Trush for helping in the preparation of the final figures. This study was supported by The Pennsylvania Breast Cancer Coalition and Friends for an Earlier Breast Cancer Test.

![*In vitro*-*in vivo* model of cell transformation. The human normal-like MCF-10F cells were treated with high dose of estradiol and named early transformed breast epithelial cells (trMCF). The trMCF cells were seeded on a Boyden chamber and the cells that invaded, bsMCF, were selected and expanded. The bsMCF cells were injected in the fat mammary pad of SCID mice producing breast tumor xenografts. These xenografts were surgically removed and tumor cells were expanded giving origin to caMCF. The trMCF cells did not produced tumors when injected in SCID mice.](IJO-44-06-1831-g00){#f1-ijo-44-06-1831}

![All-trans retinoic acid (ATRA) induces morphological changes in transformed cells trMCF clone 11. The trMCF clone 11 cells were plated in collagen matrix (3-D cultures) after being treated continuously for 26 days with different concentrations of ATRA. The cells were photograph after 8 days in collagen. (A) trMCF clone 11 cells (control); (B) trMCF clone 11 cells treated with 0.1% DMSO (vehicle, control); (C) trMCF clone 11 after being treated with 10^−5^ M (10 *μ*M) ATRA; (D) trMCF clone 11 cells after being treated with 10^−6^ M (1 *μ*M) ATRA; (E) trMCF clone 11 cells after being treated with 10^−7^ M ATRA; (F) trMCF clone 11 cells after being treated with 10^−8^ M ATRA.](IJO-44-06-1831-g01){#f2-ijo-44-06-1831}

![Spherical masses, tubules and intermediate structures formed in collagen by trMCF clone 11 before and after ATRA treatments. The trMCF clone 11 cells form spherical masses in collagen and some intermediate structures. The trMCF clone 11 cells were treated with different concentrations of all-trans retinoic acid (ATRA) for 26 days; after ATRA treatments, the cells were plated in collagen. (A) Total number of different structures in collagen of trMCF clone 11 cells before and after ATRA treatment. Total number of spherical masses (SM), tubules and intermediate structures (spherical masses with prolongations) per well are shown. (B) Different structures on collagen matrix of trMCF clone 11 cells after treatment with different concetrations of ATRA. Percentage of different structures in collagen.](IJO-44-06-1831-g02){#f3-ijo-44-06-1831}

![Invasion assay of trMCF clone 11 before and after ATRA treatments. The cell index of Matrigel-coated wells (invasion) at different time points are shown. The invasion capacity of the trMCF clone 11 did not show significant differences after 10^−5^ M ATRA (▲) or 10^−6^ M ATRA (■) compared with control after 16 h.](IJO-44-06-1831-g03){#f4-ijo-44-06-1831}

![Unsupervised sample classification by principle coordinate analysis (PCoA). Two arrays were performed for each cell line and treatment: MCF-10F (MCF_CTR1 and MCF_CTR2), trMCF clone 11 (E2_CTR1 and E2_CTR2), 10^−5^ M ATRA trMCF clone 11 (E2_Hi1 and E2_Hi2) and 10^−6^ M ATRA trMCF clone 11 (E2_Lo1 and E2_Lo2). The trMCF clone 11 cells treated with 10^−5^ M ATRA (E2_Hi) or 10^−6^ M ATRA (E2_Lo) shown a major difference with trMCF clone 11 cells (E2_CTR) and minor differences with MCF-10F cells (MCF_CTR).](IJO-44-06-1831-g04){#f5-ijo-44-06-1831}

![Representation of the gene expression studies showing number of dysregulated genes. Expression studies were performed in the early transformed trMCF clone 11 cells before and after treatment with 10^−6^ M ATRA (ATRA trMCF clone 11) and normal human breast epithelial MCF-10F cells. A total of 207 genes upregulated in the transformed trMCF clone 11 (compared to the normal MCF-10F) were downregulated after treatment with 10^−6^ M ATRA and, 236 genes that were downregulated in trMCF clone 11 (compared to MCF-10F) were upregulated by 10^−6^ M ATRA treatment. These 443 genes defined a gene signature programming the reverse-transformation effect by ATRA.](IJO-44-06-1831-g05){#f6-ijo-44-06-1831}

![Heat map of selected genes in normal breast epithelial cells and early transformed cells before and after 10^−6^ M ATRA treatment. The expressions of genes involved in cell morphology are shown; also some genes from the aryl hydrocarbon and RAR pathways and genes involved in chromatin modification are shown. The genes that were dysregulated in the early transformed breast epithelial cells (trMCF clone 11) reached normal levels, similar to the normal breast epithelial cells MCF-10F, after treatment with 10^−6^ M ATRA. Red, yellow or blue colors represent expression levels above, at or below the mean level across the samples.](IJO-44-06-1831-g06){#f7-ijo-44-06-1831}
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A, ATRA-downregulated genes (207 genes).

  ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------- ----------------- ---------------------------------------------------------
  ACSS3                                                  DNAJB9                                                  KLF11                                                   PL-5283/SLC13A4   TIMP3[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}
  ALDH3A2                                                DSC3                                                    KLHDC8B                                                 PLAG1             TMEM167B
  ALDOC                                                  DUSP5P                                                  LCA5                                                    PLD1              TMEM27
  ALPK1                                                  EFHC1                                                   LOC100288092                                            PLD6              TMEM40
  ANKRD37                                                EFNB3                                                   LOC100289187                                            PLK1S1            TMEM59
  AQPEP                                                  EPB41L4B                                                LOC100505894                                            POFUT2            TNFRSF25
  ARG2                                                   ERCC1[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}   LOC100506057/STK32C                                     POLR1D            TNFSF11
  ARHGAP19                                               ETS2[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}    LOC100507303                                            PPIL6             TNKS
  ARHGEF10                                               FABP6                                                   LOC100507547                                            PPOX              TP63
  ATF2                                                   FAM117A                                                 LOC100507644                                            PPP1R13L          TPD52L1[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}
  ATG14                                                  FAM168A                                                 LOC439938                                               PPP1R3C           TPRG1
  ATP2C2                                                 FAM46C                                                  LOC642587                                               PRKAB2            TRAF3IP2
  ATP5C1                                                 FAT2                                                    LOX                                                     PRMT2             TRAPPC6A
  BCAS4                                                  FBXO2                                                   LRIG1                                                   PROCR             TSC22D3
  BFSP1                                                  FEM1B                                                   LYST                                                    PTEN              TTBK2
  BLNK                                                   FLCN                                                    MAP2K5                                                  PTEN/PTENP1       TTC39B
  BTBD3                                                  FLJ37644                                                MAPT                                                    PTPN14            TXNIP
  C11orf80                                               FLJ45244                                                MGEA5                                                   RAB11FIP4         UFM1
  C16orf46                                               FNBP1L                                                  MGP[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}     RAB38             UGT1A1/1A4/1A6/1A8/1A9/1A10
  C17orf39                                               FNTA                                                    MLF1                                                    RAB40C            USP3
  C17orf48                                               FNTB                                                    MRAP2                                                   RAB4A             USP32
  C1orf133                                               FSIP1                                                   MXD1                                                    RAB7L1            VPS8
  C1orf161                                               FXYD2                                                   MYLIP                                                   RASSF6            WAC
  C20orf111                                              GBAS                                                    N4BP2L1                                                 RMND1             WDR59
  C21orf7                                                GGNBP2                                                  NDE1                                                    RNF169            WDR91
  C5orf41                                                GGTA1                                                   NDUFB4                                                  SCARA3            WWOX[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}
  C7orf68                                                GIT2                                                    NEK2                                                    SCRG1             YOD1
  C9orf9                                                 GJA3                                                    NEURL1B                                                 SEMA6A            ZBTB34
  CCDC28A                                                GKAP1                                                   NFKBIL1                                                 SFT2D1            ZFAND5
  CD44[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}   GNA13                                                   NGLY1                                                   SHOX2             ZNF836
  CELSR2                                                 GNAI1                                                   NMNAT3                                                  SLC25A37          ZNRF1
  CLCA2                                                  GOSR2                                                   NPL                                                     SLC2A12           
  CMBL                                                   GPM6A                                                   OGFRL1                                                  SLC2A9            
  COBL                                                   GPNMB                                                   PALMD                                                   SLC5A3            
  CRIP2                                                  H19                                                     PDCD4[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}   SOCS3             
  CSNK2A2                                                HAS3                                                    PDCD5                                                   SORL1             
  CYP1B1                                                 HBP1                                                    PDE7A                                                   SPATA17           
  CYP39A1                                                HERPUD1                                                 PDZD2                                                   STAU2             
  DBP                                                    HMGCL                                                   PER1                                                    STMN3             
  DCD                                                    IFNAR1                                                  PER3                                                    STX6              
  DDAH2                                                  IRF6                                                    PHF21A                                                  SUSD4             
  DDC[^a^](#tfn2-ijo-44-06-1831){ref-type="table-fn"}    IRX2                                                    PHLDB3                                                  TESK2             
  DDIT3                                                  KCMF1                                                   PHTF2                                                   THBS2             
  DHX40                                                  KDM5B                                                   PIK3CD                                                  THSD1///THSD1P1   
  ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------- ----------------- ---------------------------------------------------------

Genes upregulated in trMCF clone 11 that were downregulated after 10^−6^ M ATRA-treatment to similar levels found in MCF-10F are indicated.

Genes with binding sites for RARα or RARβ described by Hua *et al* ([@b29-ijo-44-06-1831]).

###### 

B, ATRA-upregulated genes (236 genes).

  ------------------------------------------------------- ------------------------------------------------------- -------------- --------------------- -------------------------------------------------------- -------------------------------------------------------
  ABHD13                                                  COX7B                                                   HIATL1         OSTM1                 SLC43A3                                                  TSPAN2
  ACP2                                                    CRELD2                                                  HIGD1A         P2RY2                 SMPDL3A                                                  UBE2N[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}
  ADAM12                                                  CST6[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}    HOXA11         PAPPA                 SNRNP25                                                  UBE2Q1
  ALDH1A3                                                 CSTF2                                                   HPGD           PARVA                 SNX19                                                    UBP1
  ANO1                                                    CYB561D2                                                HS3ST1         PCSK5                 SOAT1                                                    UNK
  AOX1                                                    DCBLD2                                                  HS6ST2         PDE12                 SPAG1                                                    VARS2
  APOL6                                                   DHRS9                                                   IFI44          PHACTR3               SPATA13                                                  VGLL3
  ARGLU1                                                  DHX9                                                    IFIT3          PHLDA1                SRPX2                                                    VSIG10
  ARHGAP26                                                DNAJA1                                                  IFIT5          PHLDA2                SRSF10                                                   ZADH2
  ARHGAP42                                                DOLK                                                    IFNAR1         PITPNC1               SRSF2IP                                                  ZBED4
  ARHGDIB                                                 DPH3                                                    KHNYN          PKIB                  SSPN                                                     ZDHHC2
  ARIH2                                                   EFCAB2                                                  KLHL18         PLCXD2                STK39                                                    ZMPSTE24
  ASPHD2                                                  EFNB2                                                   KLHL23         PLGLA/PLGLB1/PLGLB2   STS                                                      ZNF252
  ATP6V0A2                                                EHD4                                                    KRT80          PNO1                  STYK1                                                    ZNF271
  B3GALNT1                                                EIF2AK1                                                 LOC100131993   PNPLA3                SUPT7L                                                   ZNF326
  BRI3BP                                                  EIF5B                                                   LOC100505759   PODXL                 SUSD5                                                    ZNF35
  BTG1                                                    ELOVL6                                                  LOC100507192   POLR3K                SYNCRIP                                                  
  C12orf26                                                ENC1[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}    LOC283278      PPP2R1B               SYNJ2BP                                                  
  C12orf5                                                 ENY2                                                    LOC728903      PRPS1                 SYTL2                                                    
  C1GALT1C1                                               ERLIN2                                                  MACC1          PRR15                 SYTL5                                                    
  C1orf116                                                EXOG                                                    MARCKS         PSCA                  TBC1D30                                                  
  C1orf135                                                FADS1[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}   MAT2A          PSME3                 TFDP1                                                    
  C1orf212                                                FAIM                                                    MCFD2          PTGR1                 TFRC                                                     
  C1orf226                                                FAM118B                                                 MEIS3P1        PTP4A2                TGFB2                                                    
  C6orf223                                                FAM119A                                                 MFAP3L         PTPRB                 TGFBR2[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}   
  CALM1[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}   FAM83A                                                  MFI2           PTPRJ                 TGM2                                                     
  CCDC68                                                  FBXW2                                                   MFSD1          RABIF                 THSD4                                                    
  CCDC88A                                                 FDX1                                                    MICALL1        RBM25                 TIMM23                                                   
  CCND1[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}   FN1[^a^](#tfn4-ijo-44-06-1831){ref-type="table-fn"}     MMACHC         RBM45                 TIMM8A                                                   
  CDA                                                     FNIP2                                                   MRPL35         RGS17                 TIMM8B                                                   
  CDC42EP2                                                FRMD3                                                   MST1R          RHOBTB1               TLCD1                                                    
  CDH2                                                    FUCA1                                                   MTERFD3        RHOF                  TLR3                                                     
  CEP78                                                   FXN                                                     MYEOV          RPL27A                TLR4                                                     
  CFH/CFHR1                                               FZD8                                                    MYO5C          RPS6KA2               TMC5                                                     
  CFI                                                     GALNT7                                                  NAA40          S1PR3                 TMEM133                                                  
  CHAC2                                                   GATAD2A                                                 NAV3           SAMHD1                TMEM177                                                  
  CHML                                                    GBP1                                                    NECAP1         SCEL                  TMEM9B                                                   
  CHRNA5                                                  GDA                                                     NIPAL1         SGK223                TP53I3                                                   
  CLDN23                                                  GGCX                                                    NMI            SH3TC2                TPCN2                                                    
  CMAH                                                    GPATCH2                                                 NRP2           SLC16A5               TRAK2                                                    
  CNPY2                                                   GPX8                                                    NSD1           SLC1A1                TRIM45                                                   
  COL4A3                                                  GXYLT1                                                  OLAH           SLC35B4               TRIOBP                                                   
  COL4A4                                                  HAS2                                                    OR7E14P        SLC35C1               TRNT1                                                    
  COX7A1                                                  HERC6                                                   OR7E47P        SLC37A1               TSPAN12                                                  
  ------------------------------------------------------- ------------------------------------------------------- -------------- --------------------- -------------------------------------------------------- -------------------------------------------------------

Genes downregulated in trMCF clone 11 that were upregulated after 10^−6^ M ATRA-treatment to similar levels found in the normal breast epithelial cells MCF-10F.

Genes with binding sites for RARα or RARβ described by Hua *et al* ([@b29-ijo-44-06-1831]).

###### 

Canonical pathways enriched with differentially expressed genes.

                                                                                                                           trMCF clone 11 vs. MCF-10F                                                                                                                                                                              ATRA trMCF clone 11 vs. trMCF clone 11
  ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Aryl hydrocarbon receptor signaling                                                                                      ALDH1A3↓, CCND1↓, TGFBR2↓, TGM2 ↓, TFDP1↓, ALDH3A2↑, CYP1B1↑                                                                                                                                            ALDH1A3↑, CCND1↑, TGFB2↑, TGM2↑,TFDP1↑, ALDH3A2↓, CYP1B1↓
  Other genes: CDKN1A↓, JUN↓ ALDH7A1↑, CSNK2A1↑, TGFB1↑, MAPK1↑, NFE2L2↑                                                   Other genes: CCNE1↑, CCNE2↑, CDK6↑,DHFR↑, IL1B↑, IL6↑, NR2F1↑, NRIP1↑, POLA1↑ ALDH3B2↓, ARNT↓, NCOA3↓, HSPB2↓, ALDH6A1↓                                                                                 
  RAR activation                                                                                                           ALDH1A3↓, DHRS9↓, NSD1↓, TGFB2↓, CSNK2A2↑, PIK3CD↑, PRMT2↑, PTEN↑                                                                                                                                       ALDH1A3↑, DHRS9↑, NSD1↑, TGFB2↑, CSNK2A2↓, PIK3CD↓, PRMT2↓, PTEN↓
  Other genes: JUN↓, NR2F2↓, RBP1↓, CSNK2A1↑, CSNK2A2↑, MAPK1↑, MAPK14↑, TGFB1↑, GNAS↑                                     Other genes: GTF2H2↑, IGFBP3↑, MAP2K1↑, MAPK13↑, NR2F1↑, NRIP1↑, RKAR2B↑, DH10↑, CITED2↓, PNRC1↓, PRKAR1A↓, SMARCD2↓                                                                                    
  Xenobiotic metabolism signaling                                                                                          ALDH1A3↓, HS3ST1↓, HS6ST2↓, PPP2R1B↓, ALDH3A2↑, CYP1B1↑, MAP2K5↑, PIK3CD↑, UGT1A1 (and others UGT)↑                                                                                                     ALDH1A3↑, HS3ST1↑, HS6ST2↑, PPP2R1B↑, ALDH3A2↓, CYP1B1↓, MAP2K5↓, PIK3CD↓, UGT1A1 (and others UGT)↓
  Other genes: CHST15↓, ALDH7A1↑, CAMK1D↑, HDAC4↑, MAPK1↑, MAPK14↑, MGMT↑, UGT8↑, NFE2L2↑                                  Other genes: ILIB↑, IL6↑, NRIP1↑, MAP2K1↑, MAPK13↑, ALDH3B2↓, ARNT↓, CAMK2D↓, CITED2↓, MAP3K8↓, PPP2R3A↓, ALDH6A1↓, MAP3K2↓                                                                             
  Molecular mechanisms of cancer                                                                                           TGFB2↓, TGFBR2↓, CCND1↓, FZD8↓, PLCB4↓, RABIF↓, RHOF↓, GNA13↑, GNAI1↑, CD44↑                                                                                                                            TGFB2↑, TGFBR2↑, CCND1↑, FZD8↑, PLCB4↑, RABIF↑, RHOF↑, GNA13↓, GNAI1↓, CD44↓
  Other genes: CDKN1A↓, CTNNB1↓, FYN↓, IRS1↓, JUN↓, SMAD4↓, TCF4↓, XIAP↓, PIK3CD↑, TCF3↑, TGFB1↑, GNAL↑, MAPK1↑, MAPK14↑   Other genes: APC↑, CCNE1↑, CCNE2↑, CDC25A↑, CDK6↑, CYCS↑, E2F2↑, MAP2K1↑, MAPK13↑, PRKAR2B↑, RAPGEF3↑, RBL1↑, TFDP1↑, ARHGEF10↓, FOXO1↓, HHAT↓, IRS1↓, NF1↓, PAK3↓, PIK3CD↓, PRKAR1A↓, RALGDS↓, RHOV↓   

Genes downregulated (↓) or upregulated (↑) are shown. ATRA trMCF clone 11 refers to trMCF clone 11 treated with 10^−6^ M ATRA.
